Vizsgálati helyszín
The Second People's Hospital of Neijiang
Neijiang, 641000, KínaMég nincs intézményhez kötve
- 15futó vizsgálat
- 5lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 20 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis12 vizsgálat
- 2. fázis5 vizsgálat
- 2/3. fázis3 vizsgálat
- Állapot
- Fut, nem toboroz8 vizsgálat
- Toboroz6 vizsgálat
- Lezárult4 vizsgálat
- Még nem toboroz1 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Daiichi Sankyo2 vizsgálat
- Shanghai Pharmaceuticals Holding Co., Ltd2 vizsgálat
- TJ Biopharma Co., Ltd.2 vizsgálat
- 3D Medicines (Sichuan) Co., Ltd.1 vizsgálat
- Beijing Tiantan Hospital1 vizsgálat
- és még 12
Futó vizsgálatok
Toboroz
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
NCT07005336· 2. fázis· TJ Biopharma Co., Ltd.· Forrás
Fut, nem toboroz
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· 3. fázis· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Forrás
Toboroz
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· 3. fázis· Bristol-Myers Squibb· Forrás
Contact: Yu Liu, Site 0424
Fut, nem toboroz
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621· 3. fázis· Biotheus Inc.· Forrás
Fut, nem toboroz
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588· 2/3. fázis· TJ Biopharma Co., Ltd.· Forrás
Toboroz
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177· 3. fázis· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Forrás
Contact: Yu Liu, Master
Toboroz
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983· 3. fázis· Jiangsu Alphamab Biopharmaceuticals Co., Ltd· Forrás
Contact: Xujuan Wang
Toboroz
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· 3. fázis· LeonaBio· Forrás
Contact: Xujuan Wang
Toboroz
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
NCT05872347· 2. fázis· Shanghai Pharmaceuticals Holding Co., Ltd· Forrás
Contact: Xujuan Wang
Toboroz
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05860465· 2/3. fázis· Shanghai Pharmaceuticals Holding Co., Ltd· Forrás
Contact: Xujuan Wang
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224· 3. fázis· Shanghai Henlius Biotech· Forrás
Fut, nem toboroz
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
NCT05215340· 3. fázis· Daiichi Sankyo· Forrás
Fut, nem toboroz
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
KN035 for dMMR/MSI-H Advanced Solid Tumors
NCT03667170· 2. fázis· 3D Medicines (Sichuan) Co., Ltd.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek